BrightHeart offers the B-Right AI Platform, a suite of FDA-cleared software tools that integrate directly into routine prenatal ultrasound machines to guide clinicians through complete fetal exams, with a particular focus on accurate, early detection of congenital heart defects (CHD). The technology provides step-by-step imaging guidance, automated organ tracking and real-time diagnostic support, helping OB-GYNs perform faster, more complete and more confident evaluations. Peer-reviewed studies in Obstetrics & Gynecology report the platform can raise CHD detection rates above 96 % while reducing diagnostic errors. To date, the company has secured five FDA clearances and partnerships with leading academic centers, underscoring a solid regulatory and clinical foundation. Fresh capital will fund commercial launch in the United States, broaden European deployment and accelerate continued product innovation. BrightHeart positions itself as a global standard setter in prenatal imaging by embedding advanced AI into everyday clinical workflows.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2026